How does 4HG0's PB Ratio compare to its peers?

4HG0 is expensive based on its Price-To-Book Ratio (28.5x) compared to the peer average (1.1x).

How does 4HG0's PB Ratio compare vs other companies in the DE Medical Equipment Industry?

4HG0 is expensive based on its Price-To-Book Ratio (28.5x) compared to the European Medical Equipment industry average (2.2x).

What is 4HG0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 4HG0's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 4HG0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 4HG0's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Qlife Holding (DB:4HG0) - Stock Price, News & Analysis

4HG0 Stock Overview

A med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. More details

4HG0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Earnings have declined by 41% per year over past 5 years

Makes less than USD$1m in revenue (SEK69K)

Does not have a meaningful market cap (€6M)

Shareholders have been substantially diluted in the past year

+ 1 more risk

Qlife Holding AB (publ) Competitors

NanoRepro

XTRA:NN6

€18.5m

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€27.4m

aap Implantate

XTRA:AAQ1

€22.4m

Price History & Performance

Summary of all time highs, changes and price drops for Qlife Holding
Historical stock prices
Current Share Price	SEK 0.17
52 Week High	SEK 10.40
52 Week Low	SEK 0.098
Beta	0.85
11 Month Change	-20.64%
3 Month Change	-14.36%
1 Year Change	-94.59%
33 Year Change	-100.00%
5 Year Change	n/a
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	4HG0	DE Medical Equipment	DE Market
7D	-12.6%	3.2%	0.9%
1Y	-94.6%	-6.5%	7.7%

Return vs Industry: 4HG0 underperformed the German Medical Equipment industry which returned -6.6% over the past year.

Return vs Market: 4HG0 underperformed the German Market which returned 7.9% over the past year.

Price Volatility

Is 4HG0's price volatile compared to industry and market?
4HG0 volatility
4HG0 Average Weekly Movement	21.8%
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4HG0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4HG0's weekly volatility has decreased from 336% to 22% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2019	5	Thomas Warthoe	www.qlifeholding.com

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus.

Qlife Holding AB (publ) Fundamentals Summary

How do Qlife Holding's earnings and revenue compare to its market cap?
4HG0 fundamental statistics
Market cap	€491.41k
Earnings (TTM)	-€13.97m
Revenue (TTM)	€5.99k

82.1x

P/S Ratio

0.0x

P/E Ratio

Is 4HG0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4HG0 income statement (TTM)
Revenue	SEK 69.00k
Cost of Revenue	SEK 3.32m
Gross Profit	-SEK 3.25m
Other Expenses	SEK 157.71m
Earnings	-SEK 160.96m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 12, 2025

Earnings per share (EPS)	-63.66
Gross Margin	-4,710.14%
Net Profit Margin	-233,279.71%
Debt/Equity Ratio	4,334.7%

How did 4HG0 perform over the long term?

See historical performance and comparison

4HG0 Stock Overview

Risk Analysis

Qlife Holding AB (publ) Competitors

XTRA:NN6

€18.5m

DB:AUG

€6.9m

XTRA:GME

€27.4m

XTRA:AAQ1

€22.4m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: kr0.006 loss per share (vs kr27.66 loss in 3Q 2023)

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

Second quarter 2024 earnings released: kr0.006 loss per share (vs kr98.15 loss in 2Q 2023)

Qlife Participates Research Trial for People Living with PKU and Gets Positive Data

Qlife Starts Clinical Trial in China with First Biomarker on Egoo Health

New major risk - Shareholder dilution

Recent updates

Third quarter 2024 earnings released: kr0.006 loss per share (vs kr27.66 loss in 3Q 2023)

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

Second quarter 2024 earnings released: kr0.006 loss per share (vs kr98.15 loss in 2Q 2023)

Qlife Participates Research Trial for People Living with PKU and Gets Positive Data

Qlife Starts Clinical Trial in China with First Biomarker on Egoo Health

New major risk - Shareholder dilution

Qlife Holding AB (publ) to Report Q2, 2024 Results on Aug 15, 2024

First quarter 2024 earnings released: kr0.013 loss per share (vs kr0.081 loss in 1Q 2023)

Qlife Holding AB (publ) has completed a Composite Units Offering in the amount of SEK 30.150028 million.

Full year 2023 earnings released: kr0.42 loss per share (vs kr5.46 loss in FY 2022)

New major risk - Financial position

Qlife Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 05, 2024

Third quarter 2023 earnings released: kr0.014 loss per share (vs kr1.34 loss in 3Q 2022)

New major risk - Shareholder dilution

New major risk - Revenue size

Second quarter 2023 earnings released: kr0.049 loss per share (vs kr1.30 loss in 2Q 2022)

Qlife Holding AB (publ) announced that it has received SEK 4.647035 million in funding from Pensys Ab, Jinderman & Partners AB

High number of new and inexperienced directors

Full year 2022 earnings released: kr5.46 loss per share (vs kr3.04 loss in FY 2021)

Full year 2022 earnings released: kr4.93 loss per share (vs kr3.83 loss in FY 2021)

Third quarter 2022 earnings released: kr1.34 loss per share (vs kr1.10 loss in 3Q 2021)

Qlife Holding AB (publ) to Report Q3, 2023 Results on Nov 02, 2023

High number of new and inexperienced directors

Second quarter 2022 earnings released: kr1.30 loss per share (vs kr0.85 loss in 2Q 2021)

Qlife Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Develops New, Small, and Disposable Filtration Unit Able to Filtrate Plasma from Whole Blood

First quarter 2022 earnings released: kr0.99 loss per share (vs kr0.60 loss in 1Q 2021)

Full year 2021 earnings released: kr3.83 loss per share (vs kr1.92 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Qlife to Follow Up Danish Clinical Evaluation on Rapid Tests for Covid-19

High number of new and inexperienced directors

Third quarter 2021 earnings released: kr1.13 loss per share (vs kr0.25 loss in 3Q 2020)

Independent Director Niklas Marschall has left the company

Independent Director Niklas Marschall has left the company

Second quarter 2021 earnings released

Full year 2020 earnings released: kr1.92 loss per share (vs kr167 loss in FY 2019)

Qlife Holding AB (Publ) Announces CE Marks Its Covid-19 Test in the Egoo.Health System

Shareholder Returns

Price Volatility

About the Company

Qlife Holding AB (publ) Fundamentals Summary

82.1x

0.0x

Earnings & Revenue